Many drug failures are really drug delivery failures

Many drugs fail in clinical trials not because they do not work, but because they lack a proper delivery mechanism. Pankaj Karande, a Rensselaer Polytechnic Institute assistant professor of chemical and biological engineering, understands this and is trying to solve this delivery problem at its most confounding level--the brain. "You can have the best and most promising of drugs, but if it doesn't go where it is needed, then it won't be effective," Karande says in a profile on RPI's website. "There are a lot of new discoveries within the area of drug development, even related to treatment of Alzheimer's. There is not a drug discovery problem; drug delivery is really the challenge." Karande is working with grants from the Alzheimer's Association to find ways of bypassing the challenging blood-brain barrier to get medicines to their intended targets. Profile

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.